Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

Launched by RENJI HOSPITAL · Jan 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the outcomes of patients with upper tract urothelial carcinoma (UTUC) who are receiving kidney-sparing surgery, a treatment that preserves kidney function while addressing the cancer. UTUC is a type of cancer that affects the urinary system, and while the standard treatment typically involves removing the kidney and the ureter (the tube connecting the kidney to the bladder), this can lead to kidney problems for many patients. Recently, research has shown that some patients with higher-risk disease may still benefit from kidney-sparing surgery without a loss in survival rates. This study aims to understand how effective this approach is in real-world settings and whether it can be a safe option for more patients.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of upper tract urothelial carcinoma. You may be eligible if you have decided against the standard surgery or meet the criteria for kidney-sparing surgery. Participants will need to commit to follow-up visits and will be required to sign consent forms. This study will help doctors learn more about the best ways to treat UTUC while minimizing the impact on kidney health. It's an important step in improving care for patients with this challenging condition.

Gender

ALL

Eligibility criteria

• • Minimum Age: 18 Years Maximum Age: 90 Years Sex: All Gender Based: No Accepts Healthy Volunteers: No
• Criteria:
• Inclusion Criteria:
• • 1. Histopathological confirmed upper tract urothelial carcinoma;
• • 2. Refused radical nephroureterectomy, or eligible for the indications of kidney-sparing surgery;
• • 3. Participants must be willing to attend the follow-up visits;
• • 4. Sign informed consent.
• Exclusion Criteria:
• • 1. Unable to undergo kidney-sparing surgery;
• • 2. Life expectancy \< 6 months;
• • 3. Previous anti-tumor therapy against UTUC, including systemic chemotherapy, surgery, radiotherapy, or immunotherapy identifying by investigators.